Wholly Owned Pipeline
PureTech's Wholly Owned Pipeline is focused on the lymphatic system and related immunology mechanisms for the treatment of cancer and immunological, lymphatic and CNS-related disorders.
Wholly Owned Pipeline
1 | Lymphatic flow disorders, incl. lymphedema | ~1M |
Product candidate for a range of conditions involving fibrosis, inflammation and impaired lymphatic flow, including lymphedema, idiopathic pulmonary fibrosis (IPF), interstitial pneumonias, unclassifiable interstitial lung disease (uILD) and other interstitial lung disease (ILD), radiation-induced fibrosis and focal segmental glomerulosclerosis (FSGS).
1 | Serious respiratory complications that persist following COVID-19 infection |
Product candidate for a range of conditions involving fibrosis, inflammation and impaired lymphatic flow, including lymphedema, idiopathic pulmonary fibrosis (IPF), interstitial pneumonias, unclassifiable interstitial lung disease (uILD) and other interstitial lung disease (ILD), radiation-induced fibrosis and focal segmental glomerulosclerosis (FSGS).
1 | Other fibrotic & inflammatory disorders, such as IPF | ~130K (IPF or uILD) |
Product candidate for a range of conditions involving fibrosis, inflammation and impaired lymphatic flow, including lymphedema, idiopathic pulmonary fibrosis (IPF), interstitial pneumonias, unclassifiable interstitial lung disease (uILD) and other interstitial lung disease (ILD), radiation-induced fibrosis and focal segmental glomerulosclerosis (FSGS).
Preclinical | Solid tumors | >50K/year U.S. (Metastatic CRC) |
LYT-200 is an investigational, fully human, IgG4 monoclonal antibody (mAb) that is designed to target galectin-9, a protein that regulates immunosuppression and is prominently expressed in hard-to-treat cancers, such as colorectal cancer, or CRC, cholangiocarcinoma, pancreatic cancer and others.
Preclinical | Solid tumors | >50K/year U.S. (Metastatic CRC) |
LYT-210 is an investigational, fully human IgG1 monoclonal antibody (mAb) directed against the delta-1 (γδ1) chain of T cells bearing γδ1 T cell receptors (TCRs) for antibody dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis (ADCP).
Preclinical | Neurological indications |
LYT-300 is an oral form of FDA-approved allopregnanolone, which is currently marketed in the U.S. as ZulressoTM and administrated as a 60-hour intravenous infusion. Despite FDA approval, the 60-hr IV infusion has greatly limited the usage of Zulresso. Achieving oral bioavailability for allopregnanolone, a natural neurosteroid, may enable its usage across a range of neurological conditions.
| Phase completed | Phase in progress |
The BIG Idea - Moving medicine forward at PureTech
